CNS Pharma partners with MD Anderson
Cancer biopharmaceutical company CNS Pharmaceuticals has entered into a sponsored research agreement with the University of Texas MD Anderson Cancer Center to investigate cancer treatment technologies.
Shanghai Cell Therapy Group, USC partner for stem cell therapies
Shanghai Cell Therapy Group has partnered with a researcher from the University of Southern California (USC) to develop a way to culture hematopoietic stem and progenitor cells outside of the body.
Online tool tracks COVID-19 vaccine development
A new interactive online tool to track the progress of coronavirus vaccine candidates currently under development has been published by the University of Notre Dame Center for Research Computing.
CordenPharma to provide excipients for Moderna's vaccine candidate
A supplier of active pharmaceutical ingredients, CordenPharma, has inked a manufacturing agreement with Moderna. CordenPharma will manufacture large-scale volumes of Moderna's lipid excipient which will be used to manufacture Moderna's SARS-CoV-2 vaccine candidate, mRNA-1273.
Millipore, Baylor partnering on COVID-19 vaccine
MilliporeSigma and Baylor College of Medicine have announced they are working to advance a vaccine manufacturing platform to fight COVID-19. The partnership will help accelerate the vaccine candidates to phase I clinical trials.
EdiGene, Immunochina to develop CAR-T therapy
EdiGene and Immunochina have announced they are collaborating on the development of allogeneic CAR-T therapy for cancer.
Ajinomoto to manufacture COVID-19 drug for Humanigen
Biopharmaceutical contract development and manufacturing firm Ajinomoto has entered into an agreement with Humanigen for the fill-finish supply of lenzilumab. The drug is being studied in a phase III clinical trial for adult patients hospitalized with COVID-19.
AbCellera raises $105M to fund antibody drug development
Artificial intelligence-powered biotech and drug discovery platform AbCellera has closed a $105 million series B financing round to expand its capacity and more.
Thermo Fisher to operate new CSL biologics facility
Thermo Fisher Scientific has entered into a long-term lease agreement with CSL to operate a new biologics manufacturing facility in Lengnau, Switzerland.
Merck to acquire Themis for SARS-CoV-2 vaccine
Merck announced on May 26 that it has entered an agreement to acquire privately held Themis, a company that is developing a vaccine candidate for SARS-CoV-2.